


## PF-06424439

Cat. No.:	HY-108341
CAS No.:	1469284-78-3
Molecular Formula:	C <sub>22</sub> H <sub>26</sub> ClN <sub>7</sub> O
Molecular Weight:	439.94
Target:	Acyltransferase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	PF-06424439 is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC <sub>50</sub> of 14 nM <sup>[1]</sup> . PF-06424439 is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate <sup>[2]</sup> .																
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 14 nM (DGAT2) <sup>[1]</sup>																
<b>In Vivo</b>	<p>PF-06424439 (p.o.; 60 mg/kg/day; for 3 days) reduces plasma triglyceride (TG) and cholesterol levels and decreases nonsignificant in circulating lipids in mice (Ldlr<sup>-/-</sup>)<sup>[1]</sup>.</p> <p>PF-06424439 (i.v.; 1 mg/kg) shows moderate clearance in rats following intravenous administration and moderate steady-state volume of distribution (Vdss) results in a short half-life<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male low-density lipoprotein receptor (Ldlr) knockout mice (Ldlr<sup>-/-</sup>)<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>60 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>P.o.; daily; for 3 days</td> </tr> <tr> <td>Result:</td> <td>Reduced plasma TG and cholesterol levels and decreased nonsignificant in circulating lipids.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Wistar-Han rats<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>1 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>I.v.</td> </tr> <tr> <td>Result:</td> <td>Showed moderate clearance and a short half-life with t<sub>1/2</sub>=1.39 h.</td> </tr> </table>	Animal Model:	Male low-density lipoprotein receptor (Ldlr) knockout mice (Ldlr <sup>-/-</sup> ) <sup>[1]</sup>	Dosage:	60 mg/kg	Administration:	P.o.; daily; for 3 days	Result:	Reduced plasma TG and cholesterol levels and decreased nonsignificant in circulating lipids.	Animal Model:	Male Wistar-Han rats <sup>[1]</sup>	Dosage:	1 mg/kg	Administration:	I.v.	Result:	Showed moderate clearance and a short half-life with t <sub>1/2</sub> =1.39 h.
Animal Model:	Male low-density lipoprotein receptor (Ldlr) knockout mice (Ldlr <sup>-/-</sup> ) <sup>[1]</sup>																
Dosage:	60 mg/kg																
Administration:	P.o.; daily; for 3 days																
Result:	Reduced plasma TG and cholesterol levels and decreased nonsignificant in circulating lipids.																
Animal Model:	Male Wistar-Han rats <sup>[1]</sup>																
Dosage:	1 mg/kg																
Administration:	I.v.																
Result:	Showed moderate clearance and a short half-life with t <sub>1/2</sub> =1.39 h.																

### CUSTOMER VALIDATION

- 
- J Virol. 2021 Nov 10;JV10147321.
  - J Dairy Sci. 2022 Feb 15;S0022-0302(22)00089-3.
  - Dev Comp Immunol. 2021 Jul 3;104197.
  - bioRxiv. 2023 Jul 3.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

- [1]. Futatsugi K, et al. Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2). J Med Chem. 2015 Sep 24;58(18):7173-85.
- [2]. Pabst B, et al. Mechanistic Characterization of Long Residence Time Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2). Biochemistry. 2018 Dec 26;57(51):6997-7010.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA